Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin–angiotensin–aldosterone system activity in humans with obstructive sleep apnea
Authors:
- 17 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 44 (5)
Abstract
Nocturnal hypoxemia (NH) in obstructive sleep apnea (OSA) is associated with renal renin-angiotensin-aldosterone system (RAAS) up-regulation and loss of kidney function. Continuous positive airway pressure (CPAP) therapy is associated with RAAS down-regulation, though the impact of NH severity remains unknown. We sought to determine whether NH severity alters the effect of CPAP on renal hemodynamics and RAAS activity in humans. Thirty sodium-replete, otherwise healthy, OSA participants (oxygen desaturation index ≥15h -1) with NH (SpO24h/night∙4wks). NH severity was characterized as moderate (mean SpO2[MSpO2]≥90%; N=15) or severe (MSpO2<90%; N=15). Glomerular filtration rate (GFR), renal plasma flow (RPF), and filtration fraction (FF) were measured at baseline and in response to Angiotensin-II (3ng/kg/min∙30min, 6ng/kg/min∙30min), a marker of RAAS activity. Pre-CPAP, baseline renal hemodynamics did not differ by NH severity. Pre-CPAP, severe NH participants demonstrated blunted GFR (Δ30min, -9±4 vs 1±3mL/min, p=0.021; Δ60min, -5±5 vs 8±5mL/min, p=0.017) and RPF (Δ30min, -165±13 vs -93±19mL/min, p=0.003; Δ60min, -208±18 vs -112±22mL/min, p=0.001; moderate vs severe) responses to Angiotensin-II. Post-CPAP, severe NH participants demonstrated maintained GFR (112±5 vs 108±3mL/min, p=0.9), increased RPF (664±35 vs 745±34mL/min, p=0.009), reduced FF (17.6±1.4 vs 14.9±0.6%, p=0.009), and augmented RPF responses to Angiotensin-II (Δ30min, -93±19 vs -138±16mL/min, p=0.009; Δ60min, -112±22 vs -175±20mL/min, p=0.001; pre- vs post-CPAP), while moderate participants were unchanged. Correction of severe, but not moderate, NH with CPAP therapy was associated with improved renal hemodynamics and decreased renal RAAS activity in humans with OSA.Keywords
Funding Information
- Alberta Innovates – Health Solutions
- Canadian Institute of Health Research
- Alberta Health and Wellness and the Universities of Alberta and Calgary
This publication has 65 references indexed in Scilit:
- Vitamin D3 Therapy Corrects the Tissue Sensitivity to Angiotensin II Akin to the Action of a Converting Enzyme Inhibitor in Obese Hypertensives: An Interventional StudyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Executive summary of the Stages of Reproductive Aging Workshop + 10Menopause, 2012
- High Prevalence of Obstructive Sleep Apnea and Its Association with Renal Function among Nondialysis Chronic Kidney Disease Patients in JapanClinical Journal of the American Society of Nephrology, 2011
- Nocturnal Hypoxia and Loss of Kidney FunctionPLOS ONE, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-IIJournal Of Hypertension, 2010
- Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary reportJournal of Human Hypertension, 2009
- Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.Journal of Clinical Investigation, 1985
- Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.Journal of Clinical Investigation, 1983
- Reciprocal Influence of Salt Intake on Adrenal Glomerulosa and Renal Vascular Responses to Angiotensin II in Normal ManJournal of Clinical Investigation, 1974